Pursuing theranostics: a multimodal architecture approach.

Theranostics is a field of nuclear medicine which uses the same targeting vector and chelating system for both a diagnostic and therapeutic radionuclide, allowing for uniformity in imaging and treatment. This growing field requires the development of more flexible chelate systems that permit novel targeting strategies. Toward this end, a multimodal architecture has been realized, making use of a phosphazene-based core and click chemistry to achieve a flexible and customizable scaffold.

The production and separation of Tb with high specific activity at the University of Utah.

Targeted radiotherapy (TRT) is an increasingly prominent area of research in nuclear medicine, particularly in the context of treating cancerous tumors. One radionuclide of considerable interest for TRT is terbium-161 (t = 6.95 days), which undergoes beta emission and shares similar decay properties as Lu (FDA-approved as LUTATHERA® and PLUVICTO®).

Development of a Bi-Labeled Pyridyl Benzofuran for Targeted α-Therapy of Amyloid-β Aggregates.

Alzheimer disease is a neurodegenerative disorder with limited treatment options. It is characterized by the presence of several biomarkers, including amyloid-β aggregates, which lead to oxidative stress and neuronal decay. Targeted α-therapy (TAT) has been shown to be efficacious against metastatic cancer.